Onychomycosis: Quality of Studies

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 4, 2003, Pages 312-316

  Gupta, Aditya K ^a,b,e   Ryder, Jennifer E ^b   Bluhm, Robyn ^b   Johnson, Andrew ^c   Summerbell, Richard C ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; MEDICAL LITERATURE; ONYCHOMYCOSIS; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMANS; ONYCHOMYCOSIS; QUALITY CONTROL; RESEARCH DESIGN;

EID: 0242660149     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-002-0137-y     Document Type: Article

References (59)

1. Jaffe R. Onychomycosis: recognition, diagnosis, and management. Arch Fam Med 1998; 7:587-592.
2. Moher D, Jones A, Lepage L, et al. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285:1992-1995.
3. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the consort statement. JAMA 1996; 276:637-639.
4. Adetugbo K, Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 2000; 136:381-385.
5. Streiner DL, Joffe R. The adequacy of reporting randomized, controlled trials in the evaluation of antidepressants. Can J Psychiatr 1998; 43:1026-1030.
6. Bath FJ, Owen VE, Bath PMW. Quality of foil and final publications reporting acute stroke trials: a systematic review. Stroke 1998; 29:2203-2210.
7. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-1991.
8. De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trail of terbinafine 250 mg/ day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998; 38:S57-S63.
9. Baran R, Belaich S, Beylot C, et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat 1997; 8:93-97.
10. Brautigam M, Nolting S, Schopf RE, et al. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995; 311:919-922.
11. Tausch I, Brautigam M, Weidinger G, et al. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol 1997; 136:737-742.
12. Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofalvin. Arch Dermatol 1995; 131:919-922.
13. Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996; 35:110-111.
14. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37:740-745.
15. Gupta AK, Maddin S, Arlette J, et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatol Treat 2000; 11:33-37.
16. Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis 1997; 59:217-220.
17. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33:775-779.
18. De Doncker P, Decroix J, Piérard GE, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132:34-41.
19. Svejgaard EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol 1997; 77:66-69.
20. De Backer M, De Keyser P, Massart DL, et al. Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16 week oral treatment of toenail onychomycosis. A double-blind multicentre trial. In: Hay RJ ed. International Perspective on Lamisil (Series: CCT Healthcare Congress and Symposium: No 101) London: CCT Healthcare Communications Ltd, 1994, pp 39-43.
21. Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992; 304:1151-1154.
22. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl 39:36-39.
23. Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142:97-102.
24. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44:485-491.
25. Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999; 79:221-223.
26. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999; 318:1031-1035.
27. Havu V, Brandt H, Heikkila H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136:230-234.
28. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34:595-600.
29. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23:259-262.
30. Haneke E, Tajerbashi M, De Doncker P, et al. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatol 1998; 196:323-329.
31. Ling MR, Swinyer LJ, Jarratt MT, et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1995; 38:S95-S102.
32. Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38:S77-S86.
33. De Backer M, De Keyser P, De Vroey C, et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day - a double-blind comparative trial. Br J Dermatol 1996; 134(Suppl 46):16-17.
34. Korting HC, Schafer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37:2064-2068.
35. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33:775-779.
36. Jones HE, Zaias N. Double-blind, randomized comparisons of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol 1996; 35:589-590.
37. Haneke E, Abeck D, Ring J. The safety and efficacy of intermittent therapy with itraconazole for finger- and toenail onychomycosis: a multicentre trial. Mycoses 1998; 41:521-527.
38. Wang DL, Wang AP, Li RY, et al. Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Dermatology 1999; 199:47-49.
39. Kuokkanen K, Alava S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3:115-117.
40. Kejda J. Itraconazole pulse therapy vs. continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999 Jul; Spec No: 12-15.
41. De Doncker P, Van Lint J, Dockx P, et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56:180-183.
42. Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126(Suppl 39):40-46.
43. Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. J Am Pediatr Med Assoc 2001; 91:127-131.
44. Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997; 9:215-221.
45. Fraki JE, Heikkila HT, Kero MO, et al. An open-label, noncomparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Curr Ther Res Clin Exp 1997; 58:481-491.
46. Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35:587-588.
47. Ginter G, De Doncker P. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses 1998; 41:235-238.
48. Shemer A, Nathansohn N, Kaplan B, et al. Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. J Dermatol Treat 1999; 10:245-249.
49. Svejgaard E. Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Derm Venereol 1985; 65:143-149.
50. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32:750-753.
51. Arenas R, Dominguez-Cherit J, Fernandez LMA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34:138-143.
52. Torok I, Simon G, Dobozy A, et al. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. Mycoses 1998; 41:63-65.
53. Evans M, Pollack AV. A score system for evaluating random control clinical trials of prophylaxis of abdominal surgical wound infection. Br J Surg 1985; 72:256-260.
54. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - A multicenter survey of 2001 patients. Int J Dermatol 1997; 36:783-787.
55. Jadad A. Randomised Controlled Trials. City: BMJ Books, 1998, pp 1-119.
56. Bigby M, Gadenne A. Understanding and evaluating clinical trials. J Am Acad Dermatol 1996; 34:555-590.
57. Altman DG. Practical Statistics for Medical Research. London: 1st ed. Chapman and Hall, 1991, pp 440-476.
58. Bland M. An Introduction to Medical Statistics, 2nd ed. Oxford: Oxford University Press, 1995, pp 331-341.
59. Khan KS, Daya S, Jada AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156:661-666.